Novo-Catalent deal likely to be one-off — with some caveats, insiders say
An acquisition similar to Novo Holdings’ proposed $16.5 billion buy for Catalent is unlikely to happen again because it bucks the trend of pharma companies shedding manufacturing assets, according to insiders interviewed by Endpoints News.
But, if such a deal were to be repeated, it would likely stay within the realm of GLP-1s and manufacturers with underused Covid-19 sites as potentially attractive targets.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
